Navigation Links
Combined Molecular-targeted and Hormonal Therapies Offer Promise in Treating Ovarian Cancer

A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.

Several clinical trials have confirmed the role of hormone therapy in recurrent ovarian cancer treatment, especially in patients with low-grade tumors, says review author Dr. Siqing Fu, an assistant professor of oncology at the University of Texas at Houston. However, more research is needed to determine whether combining molecular-targeted therapy with hormonal therapy would be a more effective option.

Ovarian cancer is the deadliest of gynecological cancers; approximately 70 percent of patients are diagnosed in the later stages, when the 5-year survival rate drops below 25 percent. Traditional chemotherapy has proven to be generally ineffective against recurrent ovarian cancer, which has led researchers to investigate novel treatments.

While a cure is unlikely, the goals of treatment are to control tumor-related symptoms and to improve or maintain quality of life, says Dr. Fu. After surveying the latest research, combined molecular-targeted and hormonal therapy offers the greatest promise in achieving these goals and therefore deserves further investigation.


'"/>




Page: 1

Related medicine news :

1. Combined scan gives exact cancer diagnosis
2. A Protein-Rich Diet Combined With Exercise Found To Be More Effective In Weight Loss
3. Combined modality approach for effective treatment and enhanced survival in bile duct cancer
4. Vision Loss in Elderly Caused By Combined Effect of Genes and Bacterium
5. Exercise Combined with Dialysis Yields Better Results
6. Combined Anti-Fever Drug Therapy Proves Unsafe for Childhood Fever
7. A Combined Heart Pill-developed by Dr. Reddy’
8. A Combined Research for Producing Chlamydia Vaccine Begins
9. Combined Ingredients may Cut Cholesterol Levels
10. Combined Imaging Approach may Provide Better Identification of Difficult-to-diagnose Brain Clots
11. Combined Imaging Approach may Be Effective in Diagnosing Some Brain Clots
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/22/2017)... ... August 22, 2017 , ... Although Labor Day is ... many communities have begun providing weekend displays, and numerous households celebrate the unofficial end ... can be downright terrifying for pets. , Kris Zambo, owner of Dynamite ...
(Date:8/21/2017)... ... August 22, 2017 , ... Nanoparticle research provides ... and safety. By learning and implementing best practices for containment using ventilated safety ... attendees will gain a better understanding of a method for safely testing nanotechnology ...
(Date:8/21/2017)... ... August 21, 2017 , ... Los Angeles area medical group ... academic year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, M.D. This one ... and Reconstructive Surgery. The candidate will have the opportunity to work with ...
(Date:8/21/2017)... ... August 21, 2017 , ... SportsEngine, Inc. , a ... Technology Partner of North Country Region Volleyball and will power registration, scheduling, and ... with providing sport management software to their member clubs. , SportsEngine ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... place all over the country. , Outdoor running increases exposure to ultraviolet radiation, ... an increased risk of melanoma, and only half may be adequately protecting themselves ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Inc. announced today that its fully owned USA ... York City Office in Yonkers, New York ... (TWO 2 ) homecare therapy. This new East Coast location has ... under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New ...
(Date:8/8/2017)... Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on ... the second quarter ended June 30, 2017. ... to date: Continued ... lead project, BL-8040: Announced plans to ... stem cell mobilization treatment for autologous bone-marrow transplantation in ...
(Date:8/7/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... president, effective Aug. 7, 2017. ... other interests and will serve as president emeritus during a ... us in multiple leadership roles since he joined Diplomat with ... has provided decisive, strategic leadership which continues to benefit our ...
Breaking Medicine Technology: